Which choice may fit your sore joint?

How do the common choices differ?

Cortisone may ease soreness for a shorter time, but results differ. The hyaluronic acid gel aims to help the knee move more smoothly.

For platelet-rich plasma, called PRP, staff collect platelets, tiny blood pieces involved in clotting. They first draw your blood for that step.

That platelet-rich liquid is used in the aching joint. Concentrated PRP includes another step that collects more platelets.

Bone marrow care requires a draw from the pelvis, which can leave soreness there. Fat-based care requires taking body fat before it can be prepared.

Is the more involved choice always better?

A procedure with more steps doesn't always bring more relief. In one comparison, blood, marrow, fat, and cortisone groups all reported less soreness.

None of those choices clearly did better than the others. Feeling better later is welcome, but it doesn't prove which care deserves credit.

Useful studies must match both the body part and the office procedure. A knee study can't predict your shoulder's result.

In Peoria, QC Kinetix offers biologic therapies, including PRP and concentrated PRP that its care team prepares from your blood. You can compare those with exercise, pain medicine, cortisone, and hyaluronic acid gel.

What should I ask about price?

Ask for an itemized price in writing before choosing cash-pay care. It needs to list preparation, joint care, follow-up, and any proposed repeat.

You'll also want the cancellation terms and payment timing. Ask what the clinic does when the first procedure brings little relief.

Insurance may cover exercise, medicine, cortisone, or gel but not blood-based care. The office gives its fees, while your health plan explains coverage.

A larger bill doesn't mean relief will last longer. Compare the written costs with the activity you're hoping to regain.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. In a prospective randomized trial of 90 patients with Kellgren-Lawrence grade 1-3 knee osteoarthritis, bone marrow aspirate concentrate produced outcomes equivalent to - not better than - leukocyte-rich platelet-rich plasma through 24 months.

   Anz AW, et al. — Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial. Am J Sports Med, 2022. DOI: 10.1177/03635465211072554.

3. A systematic review and meta-analysis of 27 Level I studies (1,042 PRP, 226 BMAC, 1,128 hyaluronic acid patients) found PRP and BMAC both outperformed hyaluronic acid on WOMAC, VAS and subjective IKDC scores - note the BMAC evidence base is roughly one fifth the size of the PRP one.

   Belk JW, et al. — Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis. Arthroscopy, 2023. DOI: 10.1016/j.arthro.2023.03.001.

4. A Bayesian network meta-analysis of 48 randomized trials covering 9,338 knees found hyaluronic acid and PRP significantly improved pain versus placebo, and that BMAC accounted for only 2.5 percent of the studied injections - the thinnest evidence base of the four comparators.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

5. A network meta-analysis of 79 randomized trials in 8,761 patients ranked the intra-articular injectables for knee osteoarthritis on VAS and WOMAC at 1, 3, 6 and 12 months, placing the cell-based options within a crowded field rather than above it.

   Anil U, et al. — The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee, 2021. DOI: 10.1016/j.knee.2021.08.008.

6. A 2024 systematic review of 8 Level I randomized trials in 937 patients found bone marrow aspirate concentrate improved pain and function versus baseline from one month, but the comparative advantage over other injections was inconsistent across timepoints.

   Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241296555.

7. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

8. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.